Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193414 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00193414 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 72 participants.
The verdict
NCT00193414, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study is designed to study the role of an active and well-tolerated non-platinum agent, gemcitabine, in a combination regimen with pemetrexed in the first-line treatment of advanced NSCLC. This study will serve to define the role of next generation agents in a new combination regimen in the treatment of advanced NSCLC. This combination regimen may ultimately be important in further expanding treatment options for patients while improving survival, quality of life, and symptom control compared with platinum-based combination regimens - and with acceptable toxicity.
Interventions
- DRUG Pemetrexed
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2005-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193414
The ClinicalTrials.gov registry entry for NCT00193414 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT00193414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193414 about?
NCT00193414 is a clinical study titled "Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer". This study is designed to study the role of an active and well-tolerated non-platinum agent, gemcitabine, in a combination regimen with pemetrexed in the first-line treatment of advanced NSCLC. This study will serve to define the role of next generation agents in a new combination regimen in the tre...
What is the current status of trial NCT00193414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2005-05. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00193414?
The interventions under investigation include: Pemetrexed (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00193414?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.